Comfort Level Rising With Voluntary Genomic Data Submission
Executive Summary
Three years into FDA's Voluntary Genomic Data Submission program, companies are more comfortable with the agency's ability to separate the review of the voluntary data from regulatory actions, according to FDA Associate Director of Genomics Felix Freuh